Merck 2014 Annual Report Download - page 211

206 CONSOLIDATED FINANCIAL STATEMENTS → Notes to the Group accounts
The carrying amounts of “Marketing authorizations, patents,
licenses and similar rights, brands, trademarks and other” as well
as goodwill were attributable to the divisions as follows:
€ million
Remaining
useful life in
years
Biopharma-
ceuticals
Consumer
Health
Performance
Materials Life Science
Total
Dec. 31, 2014
Total
Dec. 31, 2013
Marketing authorizations, patents, licenses and
similar rights, brands, trademarks and other
Finite useful life – 2,565.4 9.9 1,071.1 1,752.5 5,398.9 4,940.1
Rebif ® 5.0 1,841.0 – – – 1,841.0 2,209.0
Gonal-f ® 4.0 379.8 – – – 379.8 474.7
Saizen® 5.0 153.7 – – – 153.7 184.4
Humira® – – – – – – 19.1
Puregon® – – – – – – 11.5
Technologies 0.5 –18.3 152.8 0.1 1,054.3 408.4 1,615.6 619.4
Brands 0.5 – 9.5 – 8.8 12.0 248.9 269.7 255.5
Customer relationships 0.5 –12.5 0.6 1.0 0.2 1,095.2 1,097.0 1,166.5
Other 3.0 –19.3 37.5 – 4.6 – 42.1 –
Indefinite useful life – 166.8 – 1.9 – 168.7 214.9
Goodwill – 1,601.5 243.1 938.2 2,911.1 5,693.9 4,583.2
Information on impairment tests of intangible assets with
indefinite useful lives
Since goodwill and other intangible assets with indefinite useful
lives are not amortized, these are subjected to an impairment test
if there are indications of impairment, or at least once a year.
In 2014, goodwill was not impaired. The assumptions used in
the goodwill impairment test are presented in Note [7].
For intangible assets with indefinite useful lives there was an
impairment loss in 2014 in the amount of €84.8 million (2013:
€1.3 million). An impairment of €37.5 million related to the asset
from the licensing agreement with Symphogen A/S, Denmark.
The discontinuation of the Phase
III development program for
tecemotide, an investigational antigen-specific cancer immuno-
therapy, led to an impairment loss of the relevant intangible asset
amounting to €18.5 million.
A further amount of €14.0 million was due to the discontinuation
of the development activities for ceralifimod (ONO-4641) for the
treatment of multiple sclerosis. All items were disclosed in the
income statement of the Biopharmaceuticals division as impair-
ment losses under other operating expenses.
In fiscal 2014, software impairments of €5.1 million (2013:
€4.3 million) were recognized in the income statement under other
operating expenses.
In 2014, no intangible assets were pledged as security for lia-
bilities.